Walmart’s stock slides as U.S. sales are hit by falling drug prices
Walmart shares fell after the retail giant said weakness in its U.S. pharmacy business weighed on comparable sales, underscoring how deflation in prescription drugs can drag on top-line results even when shopping traffic and non-pharmacy categories remain resilient.
Management pointed to a pronounced drop in average prescription prices and continued reimbursement pressure as key headwinds in the latest quarter. While prescription volumes grew, the dollars tied to those scripts declined, creating a mechanical drag on Walmart U.S. same-store sales because comps are measured in revenue, not units. The health and wellness category—including pharmacies, vision centers, and over-the-counter medicines—represents a meaningful slice of Walmart’s domestic revenue, so price deflation in that pocket can move the needle for the chain’s overall sales growth.
What’s driving the pharmacy downdraft
Several forces have converged to reduce the dollar value of prescriptions rung through Walmart’s registers:
– Generic drug deflation: Increased competition among manufacturers and a steady cadence of new generic launches have pushed prices down across many common therapies. When branded drugs lose exclusivity, the shift to far cheaper generics typically accelerates unit growth but depresses sales dollars.
– Reimbursement dynamics: Pharmacies are paid largely through fixed-fee or formula-based arrangements with pharmacy benefit managers and insurers. As those reimbursements compress or fail to keep pace with changes in acquisition costs, revenue per script can decline even if dispensing volumes rise.
– Mix shifts: Elevated demand for certain high-profile medicines—such as GLP-1 treatments for diabetes and weight management—has been volatile, influenced by coverage decisions, prior authorization hurdles, and supply constraints. Meanwhile, softness in some higher-priced categories or faster uptake of lower-cost alternatives can further dilute average ticket in the pharmacy.
– Policy backdrop: The U.S. drug-pricing environment is evolving, with Medicare price negotiations under the Inflation Reduction Act and broader scrutiny of PBMs shaping expectations and contracting. While the timing and magnitude vary by product, the directional pressure on net prices is increasingly evident at the pharmacy counter.
For a retailer like Walmart, which operates one of the nation’s largest pharmacy footprints, weaker pricing shows up plainly in comps: more prescriptions but fewer dollars per fill. That arithmetic matters even if the rest of the store is performing well.
Core retail trends remain constructive
Outside the pharmacy, Walmart continued to highlight healthy customer engagement. Grocery traffic stayed solid as shoppers prioritized everyday value. E-commerce remained a bright spot, buoyed by curbside pickup, same-day delivery, and third-party marketplace expansion. Private brands gained share as consumers traded down in certain categories, and Walmart Connect—its advertising business—delivered another quarter of robust growth, a high-margin pillar that helps offset pressure in lower-margin lines.
General merchandise trends were mixed, with improved sell-through in seasonal and home categories offset by ongoing caution in big-ticket discretionary items. Sam’s Club performed steadily, benefiting from membership growth and remodels that enhanced club experience and click-and-collect volumes.
Still, the pharmacy shortfall was enough to temper overall U.S. comp growth, leaving investors to debate how persistent the drag will be and whether non-retail profit engines—ads, membership, marketplace services—can fully counterbalance it.
What it means for profitability
The revenue hit from falling drug prices does not translate neatly to a margin story. Pharmacy tends to carry thinner gross margins than many center-store categories. In isolation, a lower mix of pharmacy sales can lift the overall gross margin rate for Walmart U.S. However, reimbursement compression and an unfavorable mix within the pharmacy basket can squeeze pharmacy profitability itself. The net effect depends on how quickly Walmart can grow higher-margin initiatives and manage operating expenses against wage, shrink, and supply chain costs.
Notably, Walmart has refocused its health strategy after exiting its clinic-based primary care venture in 2024, doubling down on core pharmacy, immunizations, specialty fulfillment, and omnichannel prescription services. Greater use of centralized fill, automation, and digital pharmacy tools could help lower dispensing costs and protect profitability even in a deflationary price environment.
Investor reaction and the road ahead
The stock’s decline reflects concern that pharmacy deflation could persist through multiple quarters, dampening headline comp growth and obscuring underlying momentum in grocery and e-commerce. Analysts also flagged the risk that continued reimbursement pressure might require additional cost actions or sharper pricing discipline in the front of store to preserve margins.
Management signaled that pharmacy headwinds are likely to remain a factor near term. The company is leaning into several mitigants:
– Expanding high-margin businesses: Accelerating Walmart Connect advertising, marketplace services, fulfillment for third-party sellers, and financial services can diversify profit streams away from pharmacy.
– Membership and loyalty: Enhancements to Walmart+ and Sam’s Club memberships aim to deepen engagement, improve retention, and drive larger baskets—benefits that can compound even if pharmacy dollars soften.
– Supply chain and automation: Investment in regional distribution centers, automated picking, and data-driven inventory management can reduce costs and improve in-stock rates, supporting margins across the box.
– Pharmacy operations: Emphasis on immunizations, medication synchronization, specialty pharmacy, and digital refills can bolster volumes and operational efficiency, partially offsetting price deflation.
Broader implications for retail and healthcare
Walmart’s experience mirrors a pattern seen across drug retailers: when price deflation hits the pharmacy counter, revenue optics deteriorate even if patient access improves. For consumers and payers, lower drug prices are a clear win. For retailers, they are a test of operational agility and diversification. The episode also underscores why large omnichannel retailers are investing in higher-return adjacencies—advertising, data, and logistics platforms—that are less exposed to commodity-like pricing dynamics in pharmacy.
What to watch next
– Pharmacy comps ex-price: Script counts, new-to-therapy starts, and adherence trends will reveal whether volume growth can outpace price declines.
– Mix of higher-priced therapies: Coverage decisions for GLP-1s and other specialty categories could swing average ticket.
– Margin trajectory: The balance between pharmacy compression and expansion in ads and marketplace will shape the earnings outlook.
– Policy shifts: Any acceleration in drug price negotiations or PBM reform could change the slope of deflation and reimbursement.
Walmart’s pharmacy challenge is real, but it is also manageable for a company with Walmart’s scale, traffic, and expanding ecosystem. The task now is to keep growing share in the aisles that matter most to customers while building profit pools that are less sensitive to the ebb and flow of prescription pricing.
